McKesson Corporation

(New York Stock Exchange)
Back to all articles
Bullish +75

GLP-1 trade? McKesson is your stock, this investor says

AI-generated analysis

πŸ“ˆ McKesson is described as an incredibly stable healthcare stock with long-term growth tied to pharmaceutical distribution demand.

πŸ’Š GLP-1 drugs represent a major growth area for the company according to investor Gordon Reid.

🌍 McKesson is the world's largest pharmaceutical distributor, handling more than one billion prescriptions annually.

πŸ‘΅ The company should benefit from aging demographics and rising drug volumes in the market.

πŸ›‘οΈ Investors appreciate McKesson for its consistency, quality, and reasonable valuation metrics.

πŸ’° Analysts rate the stock highly with 16 "Buy" ratings compared to two "Hold" ratings and zero "Sell" ratings.

🎯 The consensus price target from analysts covering the stock is US$1,002.94.

πŸ“Š McKesson shares have gained 19.31% over the past 12 months according to current data.

πŸ“ˆ Long-term performance shows significant growth with McKesson shares up 342.2% over five years.

🎲 The trading multiple is described as undemanding, suggesting a good value for investors.

Bullish Signals
  • McKesson is described as an incredibly stable healthcare name with long-term growth tied to pharmaceutical distribution demand.
  • GLP-1 drugs represent a huge growth area for McKesson, providing significant upside potential in this high-demand therapeutic class.
  • As the world's largest pharmaceutical distributor, McKesson handles more than one billion prescriptions annually, benefiting from aging demographics and rising drug volumes.
  • Shares have delivered strong momentum, gaining 19.31% over the past 12 months and an impressive 342.2% over five years.
  • The stock offers predictability, consistency, quality, and a reasonable valuation with an undemanding multiple.
  • Analyst sentiment is overwhelmingly positive, with 16 out of 18 analysts rating the stock as 'Buy' compared to none rated 'Sell'.
  • Investors have a consensus price target of US$1,002.94, suggesting significant upside from current levels.
Risk Factors
  • McKesson shares have already gained 19.31% over the past 12 months and 342.2% over five years, suggesting the stock is priced for significant further growth and may be vulnerable to correction if momentum slows.
  • The consensus price target of US$1,002.94 represents a significant upside from current levels, implying that many analysts expect continued strong performance which could lead to high valuation multiples.
Full Analysis
Gordon Reid, president and CEO of Goodreid Investment Counsel, highlighted McKesson Corp (NYSE:MCK) as a stable and attractive healthcare investment on BNN Bloomberg's Market Call on April 23, with the report updated on April 28, 2026. Reid emphasizes that GLP-1 drugs represent a significant growth opportunity for the company, noting its role as the world's largest pharmaceutical distributor that handles over one billion prescriptions annually. He attributes McKesson's long-term potential to favorable demographic trends and increasing drug volumes, describing the stock as predictable with consistent quality. Reid further pointed out that the company is trading at an undemanding multiple relative to its growth prospects. Performance data indicates McKesson shares have gained 19.31% over the past 12 months and an impressive 342.2% over five years. Analyst sentiment remains largely positive, with 16 out of 18 analysts covering the stock rating it a "Buy," two rating it a "Hold," and none assigning a "Sell." The consensus price target for the stock is set at US$1,002.94. The article also notes a discrepancy between the main financial reporting date and the biographical information provided for the author. While the news content refers to comments made in 2026, the byline details describe Rod Weatherbie as a journalist based in Prince Edward Island who has worked on Canadian property and casualty insurance since 2004 and contributed to various literary publications like The Fiddlehead. This suggests the article may be an older piece republished with updated metadata or a template insertion error regarding the author, as the financial data cited (such as the specific share gains and analyst counts) is presented within the context of a future date without clear explanation for the biographical mismatch.